Introduction {#s1}
============

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the presence of α-synuclein protein aggregates in the form of Lewy bodies in specific brain regions. These aggregates may be responsible for the onset and progression of the disease likely by promoting mitochondrial dysfunction, microglial activation, and neuroinflammatory responses, but they do not appear all over the brain at the same time. Indeed, recent publications have suggested that the α-synuclein pathology begins in the gut and travels *via* the vagal nerve up to the brain where it spreads following the six stages defined by Braak and colleagues ([@B192]; [@B101]). Although historically the hallmark of the disease has been focused on the degeneration of the substantia nigra pars compacta (SNc), it is now well accepted that the spread of α-synuclein in the brain occurs in stages and that damage to other areas precedes the degeneration of SNc neurons, affecting glutamatergic, noradrenergic, serotonergic, histaminergic, and cholinergic projection cells ([@B49]; [@B24]). This heterogeneous, progressive neurodegeneration may explain the diverse symptomatology of PD, which includes motor and non-motor alterations ([@B37]). Indeed, PD is more likely to be a multisystem disorder rather than a pure motor disease.

According to Braak's theory ([@B25]), the first α-synuclein aggregates in the central nervous system appear in the anterior olfactory structures and the dorsal motor nucleus of the vagus nerve, following by lower raphe system and the locus coeruleus (LC) in stage 2. It is not until stage 3 that the SNc is affected together with the amygdala, tegmental pedunculopontine nucleus, and the higher raphe nuclei, among others. During stage 4, α-synuclein spreads to the hippocampal formation and specific cortical areas and finally, in the last two stages (5 and 6), almost the whole cortex is damaged. This pattern of α-synuclein propagation between interconnected nuclei has also been mimicked in animal models in which α-synuclein was overexpressed by means of viral vector administration in peripheral structures ([@B154]; [@B192]; [@B193]; [@B157]). The pathological process underlying PD would consist of a prodromal period followed by a symptomatic one when the disease is often diagnosed. The presymptomatic or prodromal phase (stages 1--3) is often characterized by olfactory dysfunction, autonomic dysregulation, pain, sleep, and mood disorders while the symptomatic phase (stages 4--6) is accompanied by the classical somatomotor symptoms and impaired cognitive functioning ([@B37]; [@B23]).

Among the brain areas that undergo degeneration in the prodromal phase, the LC deserves special attention for being one of the first nuclei to develop Lewy bodies, and because LC dysfunction may be related to several of the non-motor symptoms observed in the disease. Here, we will review the functional status of the LC in PD using data from experimental models and patients. We will also analyze the potential role of the LC in PD-associated neuroinflammation, the appearance of non-motor complications, and the pharmacological therapies.

The Locus Coeruleus {#s2}
===================

The LC is a bilateral nucleus located in the upper dorsolateral pontine tegmentum and is considered the principal noradrenergic nucleus in the central nervous system ([@B4]). Although noradrenergic neurons are the biggest cell population, GABAergic interneurons also inhabit the LC making synapses and efficiently inhibit the noradrenergic neurons ([@B10]; [@B95]; [@B26]). Neurochemical content and receptor expression are also very heterogeneous containing adrenergic, GABAergic, serotonergic, glutamatergic, µ-opioid, orexin/hypocreatin, nicotinic acetylcholine, and cannabinoid receptors (reviewed in [@B15]; [@B164]). LC noradrenergic cells, as happens with SNc neurons, also contains neuromelanin which makes them specially vulnerable to neurodegeneration in PD (reviewed in [@B114] and [@B197]).

Despite being a tiny nucleus, the LC shows an enormous projecting network, influencing the activity of nuclei all over the brain. It sends descending projections to the spinal cord ([@B205]) and densely innervates ascending areas of the CNS as the amygdala, superior colliculus, paraventricular thalamic nucleus, hippocampus, olfactory bulb, dorsal raphe, and cortex, including prefrontal, orbitofrontal, anterior cingulate, and primary motor cortices ([@B64]; [@B172]; [@B110]; [@B100]; [@B34]; [@B165]; [@B98]; [@B185]; [@B120]; [@B12]; [@B105]). The SNc and the ventral tegmental area also receive modest noradrenergic innervation from the LC ([@B11]; [@B124]). By contrast, those areas with intense dopaminergic innervation as the nucleus accumbens or the striatum show discrete noradrenergic innervation ([@B117]; [@B16]; [@B53]; [@B66]). As for the afferences, the LC also receives a large variety of inputs including those from the paragigantocellularis, prepositus hypoglossi, dorsal raphe, superior colliculus, prefrontal cortex, or the SNc ([@B9]; [@B58]; [@B50]; [@B111]; [@B26]).

It is interesting to mention that although the LC does not project to nuclei highly innervated by the dopaminergic system, it can still influence dopaminergic transmission distally. Devoto and collaborators have extensively characterized that LC-tyrosine hydroxylase positive fibers can co-release not only noradrenaline (NA) but also dopamine (DA) in the cortex, including prefrontal, parietal, and occipital cortices involving α~2~-adrenoceptor-mediated mechanisms ([@B54]; [@B55]; [@B56]; [@B57]; [@B58]). More recently, other authors have also supported that LC activation promotes DA release in the thalamus and hippocampus, contributing to stress and cognitive functions ([@B174]; [@B98]; [@B206]; [@B12]).

In view of the dense noradrenergic projection network, it is easy to understand the implication of this nucleus in many physiological functions and pathological conditions. Experimental preclinical models have demonstrated the implication of the LC in arousal, cognition, anxiety, depression, pain, attention, and locomotor control ([@B8]; [@B28]; [@B44]; [@B160]; [@B34]; [@B119]; [@B182]; [@B13]; [@B91]; [@B120]; [@B12]; [@B26]; [@B109]). The availability of new technologies, as opto- and chemogenetics, that allow efficient activation/inhibition of specific anatomical projections or cellular subtypes, has provided a better understanding of those functions and unraveled that the LC is a more heterogeneous nucleus than previously proposed. Interestingly many of the pathological situations triggered by the dysfunction of the LC are present in PD, stressing the role of this nucleus in the development and management of the non-motor complications of the disease.

Noradrenergic Dysfunction in Parkinson's Disease {#s3}
================================================

Preclinical Evidence {#s3_1}
--------------------

In the last decades, researchers have shown increasing interest in further understanding the pathophysiological basis of the non-motor symptoms present in PD with special focus on the noradrenergic system. In the preclinical studies, viral-vector-induced, gene-mutated, or neurotoxin-based animal models are regularly used although the vast majority of the data come from these latter ones.

Anatomical studies using the unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rat model show that the number of LC neurons is not affected by the DA loss ([@B127]; [@B142]) but NA levels in different projection areas are variably decreased. In the prefrontal cortex of the lesioned hemisphere, some authors found unchanged ([@B51]; [@B52]) or reduced NA concentrations ([@B171]; [@B142]). Similarly, other areas with sparse noradrenergic innervation, as the striatum, show unchanged or lower NA levels ([@B171]; [@B142]). Bilateral models of 6-OHDA show, however, more robust NA deficits in the cortex and striatum ([@B196]). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys exhibit clear noradrenergic damage, including LC cell loss, lower NA concentrations in several brain regions, and reduced noradrenergic innervation of the SNc and the subthalamic nucleus ([@B150]; [@B116]). Some publications have also reported low NA striatal and cortical tissue content in MPTP mice ([@B112]; [@B137]; [@B5]). Indeed, MPTP reproduces better than 6-OHDA the heterogeneous neuronal damage produced in PD, as recently shown by a publication using matrix-assisted laser desorption-ionization mass spectrometry ([@B96]). Evidence regarding the integrity of the noradrenergic system in transgenic mice models of PD is more scarce but also stresses noradrenergic impairment. Thus, reduced tyrosine hydroxylase positive cells and α-synuclein aggregations in the LC have been demonstrated in PINK1 knockout rats ([@B84]; [@B41]), LRRK, and parkin knockout mice ([@B199]; [@B78]). However, in transgenic mice overexpressing human A53T α-synuclein, although having lower NA levels at the level of the striatum, olfactory bulb, and spinal cord, TH positive cells in the LC expressed modest α-synuclein aggregates but remained intact in number ([@B79]; [@B178]). These noradrenergic dysfunctions are accompanied by behavioral deficits, such as early vocalization and swallowing deficits.

It is also interesting to stress that in parkinsonian conditions, the noradrenergic system may contribute in some extent to the loss of dopaminergic function. In animals lesioned with 6-OHDA, noradrenergic transporter (NET) are increased possibly for compensating for the severe DA loss ([@B38]). Indeed, NET can reuptake not only NA but also DA in those regions with sparse DA innervation ([@B132]). In this line, some publications support that in absence of DA transporters, NET reuptakes L-DOPA-derived DA in the striatum and other areas, playing a possible role in L-DOPA induced dyskinesia (LID), as later discussed.

Apart from the anatomical and neurochemical changes, few electrophysiological studies using anaesthetized 6-OHDA lesioned animals, have revealed that experimental DA degeneration also impacts LC neuron basal activity and its response to antidepressant agents in parkinsonian rodents. Regarding the electrophysiological changes, increased and decreased activity was reported by different authors ([@B201]; [@B126]; [@B127]). This discrepancy may rely in methodological differences that could imply direct noradrenergic damage produced by the neurotoxins ([@B182]). On the other hand, in control rats, serotonergic and noradrenergic antidepressants interact with L-DOPA when administered together (see below). Using the forced swimming test, control rats subchronically treated with L-DOPA and fluoxetine showed reduced efficacy of the antidepressant drug, while coadministration of the NET blocker reboxetine and L-DOPA provided the opposite effect ([@B128]). At the behavioral level, regardless inconsistencies found through the scientific publications, parkinsonian animals tend to mimic the human symptomatology showing motor but also non-motor impairments ([@B189]). An array of studies report that rodents lesioned with 6-OHDA or MPTP show anxious and depressive behavior, pain, cognitive, and sleep disturbances ([@B131]; [@B145]; [@B14]; [@B198]; [@B97]; [@B36]; [@B27]; [@B59]), more notably in bilateral models of the disease ([@B65]; [@B183]; [@B159]; [@B22]; [@B196]). Although the participation of other nuclei cannot be ruled out, the role of the LC in the mentioned functions is widely accepted.

Although preclinical data to large extent support the noradrenergic affection in parkinsonian models, several discrepancies exist, which may be due to methodological variations. In this regard, especially when using the neurotoxin 6-OHDA, it should be considered that lesion protocols vary considerably among the studies, including key steps like animal age, toxin dose and injection site, magnitude of the lesions, and administration of the non-selective NET blocker desipramine to protect noradrenergic neurons from the 6-OHDA toxicity. Genetic and α-synuclein based models are less often used with considerable results variation among the studies. The use of other neurotoxins as MPTP seems to provide results that are more consistent.

Clinical Evidence {#s3_2}
-----------------

In line with the aforementioned findings reported in animal models of PD, there is substantial evidence showing degeneration of the noradrenergic system in PD patients. Numerous anatomical *post mortem* studies in PD brains have documented a moderate to severe cell loss (around 30--90%) and Lewy body pathology in the LC, equal in magnitude throughout the rostral-caudal parts of the nucleus ([@B74]; [@B35]; [@B77]; [@B17]; [@B209]; [@B121]). Specifically, neuromelanin-containing medium-size LC neurons present somatic and dendritic alterations, whereas smaller non-noradrenergic LC cells do not show severe pathological changes ([@B148]).

Although *in vivo* positron emission tomography imaging studies using non-specific ligands failed to identify the noradrenergic damage, more recent neuromelanin-sensitive magnetic resonance studies have found progressive loss of the LC signal in both idiopathic and genetic PD patients and even a lower signal in those PD patients with depressive symptoms ([@B161]; [@B31]; [@B166]; [@B204]). ^18^F-dopa positron emission tomography imaging, as an index of monoaminergic nerve terminal function, have also demonstrated a reduced uptake in the LC, indicating progressive loss of noradrenergic terminal function ([@B149]).

While the relationship between α-synuclein accumulation and neuronal death is not fully understood, it has been proposed that this protein burden may lead to neuronal dysfunction/degeneration and, therefore, impair neurotransmission ([@B63]). As explained before, Braak and colleagues established six levels of degeneration over the course of the disease where the noradrenergic impairment would occur earlier than the dopaminergic one and the subsequent primary motor symptoms. It has further been proposed that α-synuclein pathology in the LC not only precedes, but may also be of greater magnitude than that occurring in the SNc, a finding that persists across disease stages ([@B209]). These results suggest that LC dysfunction may directly contribute to disease onset and progression rather than be a collateral consequence.

Consistent with LC neuron loss and degeneration, there is a decreased noradrenergic innervation of LC target structures, including the prefrontal and motor cortex, striatum, thalamus, hypothalamus, and cerebellum ([@B102]; [@B168]; [@B149]; [@B151]; [@B176]). The atrophy of tyrosine hydroxylase-containing axons is not restricted to the central nervous system, and a prominent loss of noradrenergic innervations of the peripheral autonomic system has been demonstrated, including in the left cardiac ventricle ([@B87]; [@B184]; [@B173]).

Although plasma NA levels are elevated in *de novo* PD patients ([@B3]), neurochemical studies have reported lower levels of the neuronal NA metabolite dihydroxyphenylglycol in the cerebrospinal fluid ([@B81]), as well as marked reduction of DA-beta-hydroxylase activity, an enzyme responsible for hydroxylation of DA to NA, in parkinsonian patients ([@B92]; [@B138]). Regarding changes in adrenergic receptors in PD, an *in vitro* autoradiographic study showed upregulation of α~1~- and β~1~- and reduced density of α~2~-adrenoceptors in the prefrontal cortex of *post mortem* parkinsonian patients ([@B29]).

Despite some discrepancies in animal models, both preclinical and clinical studies support the notion that the noradrenergic system is impaired in parkinsonism. This is important for understanding the complexity of the neurodegenerative process and should be taken into account when administering drugs whose pharmacological effect relies on the integrity of this system.

Clinical Implications of Noradrenergic Dysfunction in PD {#s4}
========================================================

The degeneration of the noradrenergic system in the CNS and periphery occurring in PD is associated with a broad spectrum of non-motor symptoms that encompass autonomic, behavioral, and cognitive parameters. The appearance of these symptoms and signs cannot be just attributed to an alteration in the functioning of the noradrenergic system, as they are also known to be associated with deficits in other neurotransmission systems such as cholinergic, serotonergic, GABAergic, or glutamatergic ([@B163]). However, in this review, we will focus on non-motor complications appearing in the prodromal phase of the disease that, apart from other neurotransmitters' abnormalities, implicate malfunctioning of LC neurons.

In accordance with predicted Braak's stages, the different clinical features due to noradrenergic dysfunction can be observed along the progression of the disease ([@B88]) and, often appear before motor symptoms onset. Detecting noradrenergic impairment could be used as a diagnostic biomarker for early detection of the neurodegeneration, providing an opportunity for intervention with disease-modifying therapies ([@B18]).

Autonomic Disturbances {#s4_1}
----------------------

Sympathetic autonomic dysfunction is a common clinical feature of PD and may precede motor symptomatology, becoming more prevalent as the disease progresses ([@B163]). The most common dysautonomic symptoms are orthostatic hypotension, urogenital dysfunction, and constipation ([@B115]), but PD patients can also suffer fatigue, thermoregulatory dysregulation, excessive perspiration, or postural light-headedness. Autonomic dysfunction has a heterogeneous manifestation and its progression is not predictable, however, it is associated with reduced autonomy and a decline in quality of life, regardless of severity or duration of the disease ([@B104]). The orthostatic hypotension affects 30--58% of PD patients ([@B82]) and has been linked to peripheral sympathetic cardiovascular denervation and also in a certain degree to central autonomic involvement. PD patients with defined symptomatic orthostatic hypotension exhibit decreased LC neuromelanin signal on magnetic resonance studies ([@B175]) and low plasma levels of NA, which is associated with both supersensitivity of vascular adrenergic receptors and an up-regulation of platelet α~2~-adrenoceptors ([@B167]). As a consequence of a reduced capacity to adapt the peripheral vasculature and cerebral perfusion pressure PD patients can often manifest postural light-headedness and syncope ([@B169]). Constipation and prolonged gastrointestinal transit time affect more than 80% of PD patients and, in some cases, may lead to megacolon (for review see [@B32]). Although defecation dysfunction seems to be multifactorial, one of the proposed pathophysiological mechanisms is the accumulation of α-synuclein immunoreactive Lewy bodies in sympathetic ganglia ([@B200]). Urinary and sexual dysfunctions are also late features of PD related to degeneration of brain regions that innervate the bladder, among them the LC ([@B125]; [@B146]).

Sleep Disorders {#s4_2}
---------------

Sleep disturbances are among the most frequent PD symptoms, affecting some 60--98% of patients ([@B181]). Common sleep disorders include excessive daytime somnolence, nocturnal wakefulness, sleep attacks, REM sleep behavior disorder, or restless leg syndrome. All these sleep impairments can be early premotor manifestations and related to LC dysfunction as underlying mechanism, since this nucleus contributes to the control of arousal and sleep-wake cycle ([@B28]). In fact, *post mortem* examinations of patients with REM sleep behavior disorder without motor symptoms revealed neuronal loss and Lewy bodies in the LC ([@B191]). A recent magnetic resonance study further linked LC neuromelanin levels with amount of REM sleep without atonia in PD patients ([@B175]). Clinical management of sleep disorders in PD is complex because most of the antiparkinsonian drugs can alter sleep architecture and induce sleepiness as a side effect. Nevertheless clonazepam or melatonin are often prescribed ([@B73]).

Depression {#s4_3}
----------

Depression affects up to 40% of PD patients and may precede the onset of motor symptomatology ([@B43]; [@B170]; [@B42]). There is strong evidence for a correlation between noradrenergic function and depression in PD patients. In fact, neuroimaging and neuropathological studies have demonstrated reduced LC projections to limbic brain areas (cingulate cortex, thalamus, ventral striatum, or amygdala), as well as gliosis and cell loss at LC level, which was more pronounced in patients with higher frequency of depression or anxiety ([@B153]; [@B71]). As in major depression, selective serotonin reuptake inhibitors, tricyclic antidepressants, serotonin and NA reuptake inhibitors, and monoamine oxidase inhibitors are used in the pharmacotherapy, with partial effect, probably influenced by the neurodegeneration of the serotonergic and noradrenergic systems ([@B158]). The use of antidepressant that do not target monoaminergic systems may potentially offer benefit in these patients ([@B194]).

Cognitive Manifestations {#s4_4}
------------------------

The loss of LC neurons and decreased noradrenergic innervation of forebrain targets are associated with cognitive dysfunction in PD ([@B30]; [@B155]; [@B195]; [@B175]). In early PD, subtle cognitive deficits include difficulty in executing functioning, particularly cognitive flexibility, which is the capacity to update and redirect attention when the environmental or homeostatic conditions change. Flexibility in cognitive processing is an essential function of prefrontal cortex and it has been proposed that loss of prefrontal noradrenergic input may contribute to this prodromal cognitive deficit ([@B195]). In late stage PD, dementia can occur with a prevalence of 24--31% ([@B1]). Although dementia in PD is related to a substantial reduction in cortical cholinergic markers, there is also evidence for a more severe loss of noradrenergic input from the LC to cortical areas ([@B35]). The severity of dementia has been linked to the loss of LC neurons in some studies ([@B210]; [@B48]; [@B107]).

Noradrenaline, Neuroinflammation, and Neuroprotection {#s5}
=====================================================

It is important to mention that NA might protect DA neurons from damage and therefore, integrity of the noradrenergic system may condition the progression of the disease. In this sense, preclinical data from MPTP mice and marmosets suggest that damaging the LC leads to a loss of DA neurons in the SNc followed by more pronounced motor deficits ([@B118]; [@B113]; [@B21]; [@B67]; [@B68]; [@B207]; [@B106]). Conversely, the damage produced by MPTP is reduced when the synthesis of NA is boosted ([@B99]; [@B7]) or the NET is knocked out ([@B156]). A recent publication using mutant mice characterized by the progressive degeneration of dopaminergic neurons demonstrated that chronic pharmacological NET blockade ameliorates such degeneration and the subsequent motor impairment ([@B103]). Peripheral administration of the NET blocker atomoxetine also reduced DA damage in a lipopolysaccharide inflammatory rat model of PD ([@B208]). Direct noradrenergic damage by the administration of the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (or DSP-4) also produces motor deficits and DA cell loss in control rats ([@B2]). In another recent publication, DSP-4 developed motor and non-motor symptoms in control mice and exacerbated motor disability in mice rendered parkinsonian by the injection of lipopolysaccharide ([@B177]). Some studies performed in 6-OHDA lesioned rodents also suggest that noradrenergic lesions in parkinsonian rats augment dopaminergic neuron vulnerability ([@B140]) leading to lower DA levels ([@B179]) and worsening motor performance ([@B179]; [@B180]; [@B202]; [@B171]; [@B142]). Other studies using the same 6-OHDA model failed, however, to reproduce the latter findings ([@B51]; [@B86]; [@B140]; [@B171]).

The mechanism underlying the neuroprotective effect of NA on DA degeneration is not well understood, although several lines of evidence point at the anti-inflammatory properties of NA as one factor responsible of such an effect. Both PD patients and animal models of the disease show reactive astrogliosis, astrocytic dysfunction, and microglial activation, which has been proposed as the origin of neuroinflammation ([@B143]; [@B75]; [@B80]; [@B188]; [@B108]; [@B190]). Importantly, by controlling microglial activation NA is able to halt the damage of dopaminergic neurons. Studies performed in cell cultures and animal models suggest that NA suppresses neuroinflammation by acting, at least in part, on b~2~-adrenergic receptors, which are highly expressed in glial cells ([@B133]; [@B187]; [@B207]). Low concentrations of NA or long acting β~2~-agonists are able to inhibit the microglial production and release of chemokines, interleucines, tumor necrosis factor (TNF-α), superoxide or nitric oxide, among others, ([@B133]; [@B122]; [@B152]) or to stimulate the synthesis of interleukin-1 receptor antagonists ([@B123]). Pharmaceutical strategies for increasing NA levels also attenuate nigral microglial activation and ameliorate the behavioral deficits in parkinsonian rats ([@B208]). Other authors have also proposed that in addition to the β~2~-mediated mechanisms, NA can impact inflammation by inhibiting NADPH oxidase-generated superoxide ([@B94]). Additionally, β~2~-agonists and NET inhibitors can also induce release of neurotrophic factors from astrocytes promoting neuroprotection and regeneration ([@B208]).

By contrast, NA deficit accelerates dopaminergic neurodegeneration by promoting inflammation, diminishing neurotrophic factors and promoting oxidation in the SN ([@B207]; [@B2]). In this sense, a recent publication observed that additional lesion of the LC in animal models of PD promotes enhanced release of interleukins and cytokines, likely due to an incorrect microglial function, and aggravates DA neuron degeneration ([@B207]) although some authors fails to confirm this cell loss ([@B93]). As commented before, combined dual NA/DA lesions lead to more severe phenotype including motor and non-motor symptomatology, probably due to the higher inflammatory response and faster cell loss ([@B19]; [@B177]). The implication of NA in neuroinflamation and neuroprotection could have an important translational impact in the clinic. In this sense, a long-term prospective observatory study has reported that those patients with chronic respiratory diseases, that are chronically treated with β~2~-adrenergic agonists may have a lower probability of developing PD ([@B130]). One of the reasons for this neuroprotective effect may not only rely on microglial activation, but also on the ability of b~2~-adrenoceptors to down regulate expression of human α-synuclein genes and moderate protein expression. When looking for new neuroprotective therapies, it may be relevant to assure a good NA tone for minimizing the contribution of neuroinflammation to the neuropathology.

L-DOPA and the Noradrenergic System {#s6}
===================================

L-DOPA is still considered the most efficient anti-parkinsonian drug. It is a metabolic precursor of NA through its decarboxylation into DA by the aromatic amino acid decarboxylase and the β-hydroxylation of DA by the DA beta-hydroxylase. Unfortunately, L-DOPA is poorly effective against non-motor symptoms, does not control some later-onset motor problems like freezing or "wearing-off" fluctuations, and its long-term use is associated with dyskinesia and hallucinations ([@B139]; [@B90]). The contribution of the noradrenergic system to LID has been investigated in animal models using NA/DA neurotoxic lesions. Although some studies report no implication of the noradrenergic system ([@B145]; [@B140]; [@B142]), others have demonstrated that additional noradrenergic lesion worsens dyskinetic movements in parkinsonian rodents chronically treated with L-DOPA ([@B72]; [@B127]; [@B171]). Interestingly, in one study, the authors induced the noradrenergic lesion to already dyskinetic animals, showing an increase in the duration of the dyskinetic effect of L-DOPA probably due to impaired striatal DA clearance ([@B127]).

Some noradrenergic drugs have proven antidyskinetic properties in experimental animal models of LID. The α~2A~-adrenoceptor antagonist idazoxan, reduced LID, and delayed their onset without compromising the motor score in MPTP-treated monkeys. Idazoxan prevented LID appearance while increasing the locomotor response to L-DOPA ([@B89]; [@B85]; [@B70]). Additional α~2A~-adrenoceptor antagonists have proven similar antidyskinetic properties ([@B83]; [@B89]; [@B85]; [@B162]; [@B69]). Other noradrenergic drugs, as the β-adrenergic receptor antagonist propranolol and the α~2~-receptor agonist clonidine also showed antidyskinetic effects in MPTP-treated monkeys, at the cost of reducing the antiparkinsonian efficacy ([@B83]). Experiments performed in 6-OHDA lesioned rats support the prodyskinetic action of the α~2~-antagonist atipamezole and the antidyskinetic effect of propranonol, clonidine, or idazoxan, which did not worsen motor performance ([@B47]; [@B76]; [@B20]; [@B141]). These findings suggest that the limited though beneficial effect of clonidine on LID is probably indirect due to the stimulation of somatodendritic α~2~-receptors, which inhibit noradrenergic neuronal activity and NA release. Some authors also suggest that the antidyskinetic effect of clonidine may be related to its sedative properties ([@B76]). Conversely, the antidyskinetic action of idazoxan, even if it enhances brain NA release by antagonizing α~2~ autoreceptors, could be related to the blockade of α~2~-receptors expressed by NA receptive cells at terminal levels. In any case, the overall picture is complex due to the involvement of the other adrenergic receptor subtypes in LID. The resulting effect of an overall increase in NA extracellular on LID is thus uncertain. In contrast to the beneficial effect of reboxetine ([@B171]), other NET inhibitors including desipramine have been reported to aggravate LID ([@B6]; [@B39]; [@B40]).

As mentioned above, noradrenergic mechanisms are involved in non-motor symptoms and shape the responses to other medications such as antidepressant drugs ([@B61]; [@B62]; [@B127]; [@B128]). Noradrenergic neurons may also be involved in the effects of L-DOPA, but the preclinical data are not clear. For instance, participation of noradrenergic neurons in the ability of L-DOPA to enhance DA extracellular levels is likely an indirect effect that requires the dorsal raphe nucleus ([@B186]; [@B135]; [@B134]; [@B46]; [@B129]). In dyskinetic rats, lesion of noradrenergic terminals or neurons did not reduce L-DOPA-stimulated extracellular levels of DA in the striatum ([@B136]; [@B142]). However, the noradrenergic lesion enhanced the effect of L-DOPA in extrastriatal regions in part due to the loss of clearance of extracellular DA by noradrenergic fibers bearing NET ([@B136]). Another study found that the noradrenergic lesion with DSP-4 potentiates L-DOPA-induced rotations, although this behavioral effect is not directly related to DA extracellular levels ([@B144]). Evidence suggests that the noradrenergic system participates in the effect of L-DOPA, but preclinical data are difficult to extrapolate to PD patients because the noradrenergic fibers, at least from the LC, are damaged (see above). It is also important to bear in mind that extracellular striatal DA levels induced by L-DOPA in the striatum neither parallel motor effects nor abnormal motor effects ([@B46]).

Although behavioral data support that noradrenergic drugs can modulate the effect of L-DOPA, the potential effect of L-DOPA on NA content or neuron activity is less clear. In the LC, low doses of L-DOPA did not alter the electrical tonic activity of noradrenergic neurons in control rats ([@B128]). *Post mortem* data vary, reporting no effect, or a decrease in NA tissue concentration in response to L-DOPA administration depending on the dose regimen and the brain region studied (for review see [@B46]). Acute or chronic L-DOPA increased NA tissue level in the prefrontal cortex of normal macaques, but the same regimen decreased NA tissue level in the prefrontal cortex and the amygdala of MPTP-treated monkeys whether they were dyskinetic or not ([@B60]). The only difference regarding NA tissue levels between non-dyskinetic and dyskinetic monkeys was found at the level of the motor cortex. Studies on L-DOPA-evoked extracellular levels of NA also show inconclusive results. In this regard, the latest publications have reported a substantial increase in striatal NA release after L-DOPA administration ([@B203]; [@B142]). However, in one study NA levels were still excessive after noradrenergic neurons were destroyed ([@B142]). It is likely that other electrochemically active compounds were confounding the chromatograms ([@B33]). Other data indicate that L-DOPA either inhibits or does not alter NA release in the cortex ([@B45]; [@B147]).

Conclusion {#s7}
==========

The identification of noradrenergic mechanisms in PD is crucial for understanding autonomic functions and non-motor symptomatology, and drugs that target this system may have a beneficial impact in the quality of life of the patients. One major difficulty is to extrapolate the results from animal models to patients where those alterations are variable and depend on the stage of the disease. Meanwhile, the involvement of the noradrenergic system in L-DOPA induced therapeutic effects is controversial, and noradrenergic strategies to limit the side effects accompanying anti-parkinsonian drugs are still not firmly established. In summary, and taking into account that noradrenergic system pathophysiology is a common feature of PD with other neurodegenerative diseases, such as Alzheimer's disease or atypical neurodegenerative dementias, maintenance of this system integrity may provide a common viable therapeutic option as neurodegenerative diseases-modifying strategy.
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